Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL23R | Q5VWK5 | 20/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31084118 | 0.85 | NPY4R (0.48) | IL23R | |
| SCHEMBL31084119 | 0.85 | NPY4R (0.48) | IL23R | |
| SCHEMBL18264779 | 0.84 | TLR2 (0.44) | IL23R | |
| SCHEMBL29442120 | 0.83 | RXFP1 (0.43) | IL23R | |
| SCHEMBL31238569 | 0.82 | IL23R (0.51) | IL23R | |
| SCHEMBL16508450 | 0.82 | TFPI (0.54) | IL23R | |
| SCHEMBL19441727 | 0.82 | NPY4R (0.49) | IL23R | |
| SCHEMBL17849843 | 0.82 | NPY4R (0.51) | — | |
| SCHEMBL31737829 | 0.82 | CXCR4 (0.44) | IL23R | |
| SCHEMBL30782822 | 0.82 | IL23R (0.45) | IL23R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9169289-B2 | Peptide derivatives for treatment, prevention or alleviation of a condition associated with bone loss or low bone density or to inhibit osteoclast differentiation and stimulation | STRONGBONE AB (SE) | 2015-10-27 | — | — | US | disclosed |
| US-20140243274-A1 | NOVEL PEPTIDE DERIVATIVES FOR TREATMENT, PREVENTION OR ALLEVIATION OF A CONDITION ASSOCIATED WITH BONE LOSS OR LOW BONE DENSITY OR TO INHIBIT OSTEOCLAST DIFFERENTIATION AND STIMULATION | STRONGBONE AB (SE) | 2014-08-28 | — | — | US | disclosed |
| US-8748370-B2 | Peptide derivatives for treatment, prevention or alleviation of a condition associated with bone loss or low bone density or to inhibit osteoclast differentiation and stimulation | STRONGBONE AB (SE) | 2014-06-10 | — | — | US | disclosed |
| US-20120108515-A1 | NOVEL PEPTIDE DERIVATIVES FOR TREATMENT, PREVENTION OR ALLEVIATION OF A CONDITION ASSOCIATED WITH BONE LOSS OR LOW BONE DENSITY OR TO INHIBIT OSTEOCLAST DIFFERENTIATION AND STIMULATION | NEOBIOTICS AB (SE) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108515-A1 | NOVEL PEPTIDE DERIVATIVES FOR TREATMENT, PREVENTION OR ALLEVIATION OF A CONDITION ASSOCIATED WITH BONE LOSS OR LOW BONE DENSITY OR TO INHIBIT OSTEOCLAST DIFFERENTIATION AND STIMULATION | BMP2, SOST, BMP1 | IL23R 1006/4885 |
| US-20140243274-A1 | NOVEL PEPTIDE DERIVATIVES FOR TREATMENT, PREVENTION OR ALLEVIATION OF A CONDITION ASSOCIATED WITH BONE LOSS OR LOW BONE DENSITY OR TO INHIBIT OSTEOCLAST DIFFERENTIATION AND STIMULATION | BMP2, CALCRL, ARG1 | IL23R 412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.